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Abstract: Various coding genes representing multiple functional categories are downregulated in blood mononuclear cells 
(BMC) of patients with sporadic Alzheimer disease (AD). Noncoding microRNAs (miRNA) regulate gene expression by 
degrading messages or inhibiting translation. Using BMC as a paradigm for the study of systemic alterations in AD, we 
investigated whether peripheral miRNA expression is altered in this condition. MicroRNA levels were assessed using the 
microRNA microarray (MMChip) containing 462 human miRNA, and the results validated by real time PCR. Sixteen AD 
patients and sixteen normal elderly controls (NEC) were matched for ethnicity, age, gender and education. The expression of 
several BMC miRNAs was found to increase in AD relative to NEC levels, and may differ between AD subjects bearing one 
or two APOE4 alleles. As compared to NEC, miRNAs signiﬁ  cantly upregulated in AD subjects and conﬁ  rmed by qPCR were 
miR-34a and 181b. Predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs 
were largely represented in the functional categories of Transcription/Translation and Synaptic Activity. Several miRNAs 
targeting the same genes were within the functional category of Injury response/Redox homeostasis. Taken together, induction 
of microRNA expression in BMC may contribute to the aberrant systemic decline in mRNA levels in sporadic AD.
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Introduction
MicroRNA are noncoding small RNA that bind target sites either in the 3′ untranslated region (UTR) 
of mRNA to inhibit translation or at the coding regions to degrade the messages (Lee et al. 1993; Ruvkun 
et al. 2004; Ambros, 2004; Lim et al. 2005). Mature microRNAs (miRNA) are approximately 22 
nucleotides in length and are expressed under the control of an RNA polymerase II promoter. The 
catalogue of human miRNA has expanded substantially in the last few years and the number of miRNA 
species is predicted to be close to one thousand (Hammond, 2006). Loss-of-function mutations have 
greatly facilitated elucidation of the biological functions of miRNA (Ambros, 2004) including their 
roles in development, cell differentiation (Ambros, 2004; Ouellet et al. 2006), lifespan (Boehm and 
Slack, 2005) and in diseases such as cancer (Hammond, 2006) and neurodegeneration (Bilen et al. 
2006a). In mammals, neural tissues are believed to manifest the most complex and speciﬁ  c miRNA 
expression patterns relative to other organs (Babak et al. 2004; Strauss et al. 2006).
Alzheimer disease (AD) is a dementing illness characterized by progressive neuronal degeneration, 
gliosis, and the accumulation of intracellular inclusions (neuroﬁ  brillary tangles) and extracellular 
deposits of amyloid (senile plaques) in discrete regions of the basal forebrain, hippocampus, and asso-
ciation cortices (Chertkow et al. 2001; Selkoe, 1991). The etiology of sporadic AD is likely multifacto-
rial, with carriage of the apolipoprotein E ε4 (APOE4) allele constituting a strong risk factor for the 
development of this condition (Kamboh, 2004).
Gene expression studies in AD have shown substantial downregulation of various mRNA species in 
brain (Pasinetti, 2001), peripheral blood mononuclear cells (BMC) (Maes et al. 2006) and lymphocytes 
(Scherzer et al. 2004) relative to non-demented control values. Furthermore, numerous investigations have 
implicated impairment of protein synthesis in AD tissues (Keller, 2006) and diminished concentrations 
of speciﬁ  c proteins in the cerebrospinal ﬂ  uid (CSF) of these patients (Puchades et al. 2003). In a small 
study of 13 miRNAs, levels of miR-9, miR-125b, and miR-128 were found to be increased in human AD 
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hippocampus relative to control values (Lukiw, 
2007). In light of the above, we hypothesized that 
augmented miRNA expression may be responsible 
for the suppression of speciﬁ  c mRNA species both 
in AD brain and peripheral tissues. To test this 
hypothesis in the latter, we screened 462 human 
miRNA (from let-7 family to miR-663) in BMC 
derived from well-characterized cases of mild spo-
radic AD and age-matched normal elderly control 
subjects and, based on predicted miRNA targets, 
ascertained whether the accruing data may account 
for the patterns of mRNA downregulation in 
Alzheimer BMC previously reported by our labo-
ratories (Maes et al. 2006).
Materials and Methods
Subjects
This study was approved by the Research Ethics 
Committee of the Sir Mortimer B. Davis Jewish 
General Hospital (JGH). Written informed consent 
was obtained from all patients or their primary 
caregivers. Recruited patients with sporadic AD 
were assessed by a neurologist or geriatrician at the 
JGH-McGill University Memory Clinic, a tertiary 
care facility for the evaluation of memory loss in 
Montreal. All AD subjects underwent formal neu-
ropsychological testing as previously described 
(Chertkow et al. 2001; McKhann et al. 1984). Nor-
mal elderly controls (NEC) were recruited from 
Family Practice Clinics at the JGH. The latter scored 
within one SD of age- and education-standardized 
normal values on a series of memory and attention 
tests. The Mini-Mental State Examination (MMSE) 
(Folstein et al. 1975) was administered to all sub-
jects. Subjects with chronic metabolic and inﬂ  am-
matory conditions or acute illness were excluded 
from the study. Student’s unpaired t-test was per-
formed to assess statistical differences in age, years 
of formal education and MMSE scores between 
groups. Apolipoprotein E genotyping was per-
formed as previously described (Maes et al. 2006). 
APOE4-positive persons were deﬁ  ned as individuals 
bearing one or two APOE4 alleles.
Blood samples and extraction
Whole blood was collected and BMC were isolated 
as previously described (Maes et al. 2006). The 
cell pellet was lysed in Trizol (Invitrogen, Canada) 
and immediately stored at –80 °C until further 
processing. Extraction of RNA was performed as 
described by Lacelle et al. 2002 (Lacelle et al. 
2002). Brieﬂ  y, for 1 mL of Trizol, 0.2 mL of chlo-
roform was added and mixed for 15 seconds. After 
3 minutes incubation at room temperature (RT), 
the samples were centrifuged at 12,000 g (4 °C) 
for 15 min. The upper aqueous layer containing 
RNA was transferred to another microcentrifuge 
tube for RNA extraction. Total RNA was solubi-
lized in DEPC-treated water and puriﬁ  ed using 
RNeasy Mini columns (Qiagen, Canada) according 
to manufacturer instructions.
Small RNA enrichment was performed accord-
ing to Park et al. 2002 (Park et al. 2002). Total RNA 
samples were adjusted to 400 µL with RNase-free 
water and then 50 uL of NaCl (5M) and 50 uL PEG 
8000 (v/v 50%) were added. The sample was incu-
bated on ice for 2 hours, and centrifuged for 10 
minutes at 13 000 rpm (4 °C). Supernatant contain-
ing small RNA was transferred to a microcentrifuge 
tube and 50 uL of sodium acetate (3M, pH 4.6) and 
1 mL of 100% ethanol were added. The samples 
were mixed and incubated at −20 °C for 2 hours 
and centrifuged for 10 minutes at 12 000 g (4 °C). 
The supernatant was discarded, and the pellet was 
washed with 1 mL of cold 75% ethanol and, 
centrifuged for 10 minutes at 12 000 g (4 °C). The 
pellet was dried and dissolved in 12 µL of 
RNase-free water at 60 °C for 10 minutes. Nucleic 
acid concentrations were determined at 260 
nm by spectrophotometry and samples were 
stored at −80 °C.
MicroRNA proﬁ  ling
We applied rigorous selection criteria on samples to 
control for ethnicity, health status, age and educa-
tion. Only samples with good yields in total RNA 
and small RNA enrichment were used (Supplemen-
tary Table 1). Small RNA samples were labeled with 
digoxigenin (DIG) at the 3′ end using the DIG Oli-
gonucleotide Tailing Kit, 2nd Generation (Roche 
Diagnostics, U.S.A.). One µg of small RNA was 
labeled in a total volume of 20 µL as described by 
Wang et al. (Wang et al. 2002). The human 
microRNA microarray (MMChip) consisted of 462 
human anti-sense DNA sequences of microRNAs 
obtained from miRBase (http://microrna.sanger.
ac.uk/) and spotted on nitrocellulose membrane as 
described (Wang et al. 2002). Microarray chips 
were pre-hybridized in 1 mL of DIG Easy Hyb 
solution (Roche Diagnostics, U.S.A.) at 42 °C for 265
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1 hr. DIG-labeled small RNAs from one human 
subject were added to the membrane and hybridiza-
tion was performed at 42 °C for 16 hrs. The membrane 
was washed twice (5 min) in solution 1 (2 × SSC, 
0.1% SDS) at RT, incubated for 20 minutes at 37 °C 
in solution 2 (0.5 × SSC, 0.1% SDS), and 5 minutes 
in 1× maleic acid solution (100 mM maleic acid, 
150 mM NaCl, pH 7.5) at RT. The membrane was 
blocked in 1.5% Blocking reagent (w/v; Roche 
Diagnostics, USA). The membrane was incubated 
for 30 minutes with 1:1500 Anti-Digoxigenin-AP 
Fab fragments (Roche Diagnostics, U.S.A.). The 
miRNAs hybridized on the MMchip were revealed 
by the alkaline phosphatase chromogenic reaction 
of NBT/BCIP dye as per manufacturer’s instructions 
(Roche Diagnostics, U.S.A.).
Only MMchips with excellent hybridization 
intensities were analyzed. Hybridization intensities 
were measured using an Expression 1680 scanner 
(Epson, U.S.A.) and data acquired using Array-Pro 
Analyzer 4.5 software (Media Cybernetics, MD, 
USA). Net intensity was derived from whole cell area 
measurement and corrected using mean intensity of 
ring background of surrounding spots. Microarray 
data analyses were performed with SAM software, 
version 3.02 (Signiﬁ  cance Analysis of Microarrays, 
Stanford University, CA, U.S.A.). The variable 
“Block” was used to account for the experimental 
batches (block effect). Kolmogorov—Smirnov statis-
tics were generated by Gene Set Enrichment Analysis 
(GSEA) software (Subramanian et al. 2005).
Hierarchical clustering analysis was performed 
using GenePattern software (www.broad.mit.edu/
cancer/software/genepattern/; Broad Institute, MA, 
U.S.A.) Functional attribution of correlated gene 
targets was made according to the SOURCE database 
(http://source.stanford.edu) and Gene Ontology Tree 
Machine (http://bioinfo.vanderbilt.edu/gotm).
QRT-PCR validation
For real time PCR validation, 0.1 µg of small RNA 
were quantiﬁ  ed using the NCode qRT-PCR kit 
(Invitrogen, U.S.A.). Mature DNA sense sequences 
of tested miRNAs were used as forward PCR prim-
ers. 5S rRNA served as reference gene, and was 
probed using an internal forward primer (CAGGGTC-
GGGCCTGGTTAGTACTTG).
For the miRNA let-7f, the qRT-PCR was per-
formed using the TaqMan MicroRNA Reverse 
Transcription kit, TaqMan MicroArray assay (hsa-
let-7f, RT 382) and TaqMan Fast Universal PCR 
(No AmpErase UNG; Applied Biosystems, U.S.A.) 
with 1 ng of small RNA. The TaqMan speciﬁ  c 
primer U24 small nucleolar RNA (RNU24, RT 
1001) was used as reference gene.
All real time PCR reactions were performed on 
a 7500 Fast System Real Time PCR cycler (Applied 
Biosystems, U.S.A.) according to manufacturer’s 
instructions. MicroRNA fold changes between 
diagnostic groups or genders were calculated by 
the delta Ct method.
Results
MicroRNA expression 
in Alzheimer BMC
Mean ages between the NEC (76 ± 6 years) and AD 
(78 ± 5 years) groups were not signiﬁ  cantly different 
(p = 0.26; Supplemental Table 1). Subjects in the AD 
group had fewer years of formal education (12.6 years 
Table 1. Upregulated microRNA in Alzheimer BMC.
MicroRNA  Fold change  Score (d)  q-value (%)  BMC targets (%)
a
hsa-miR-34a 1.2  1.3  0.0  21.7
hsa-miR-579 1.2  1.2  0.0  12.3
hsa-miR-181b 1.4  1.1  0.0  31.3
hsa-miR-520h 1.1  1.0  0.0  -
hsa-miR-155 1.2  0.9  5.1  -
hsa-miR-517* 1.1  0.9  5.1  11.3
hsa-let-7f 1.1  0.8  5.1  16.0
hsa-miR-200a 1.1  0.7  5.1  7.5
hsa-miR-371 1.1  0.7  5.1  -
False discovery rate (q-values) was 5.1% of 16 signiﬁ  cant miRNAs.
aPredicted targets were determined for miRNAs having scores (d) higher than 1.0 or 0% q-values in both Tables 1 and 2.266
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as compared to 15 years for NEC, p = 0.05) and 
scored signiﬁ  cantly lower on the MMSE (23/30 as 
compared to 29/30 for NEC, p  0.0001). Yields in 
small RNA enrichment did not signiﬁ  cantly differ 
between NEC and AD samples (p = 0.95).
The study consisted of 16 NEC and 16 AD 
miRNA expression proﬁ  les, analyzed in four inde-
pendent experimental blocks with equal numbers 
of women and men. Only upregulated miRNA 
expression was found to be signiﬁ  cantly altered in 
Alzheimer BMC by T-statistics (Table 1). The 
relative increases in miRNA in Alzheimer BMC 
were modest, in the range of 1.1 to 1.4-fold. Sig-
niﬁ  cant microarray data analyzed by SAM (Table 1) 
was subsequently ranked by Kolmogorov—Smirnov 
statistics using the Gene Set Enrichment Analysis 
(GSEA) software (Subramanian et al. 2005). The 
enrichments of the signiﬁ  cant upregulated miRNA 
were conﬁ  rmed for miR-34a and 181b. (Fig. 1A). 
Although miR-155 was ranked in second position, 
the fold increase in AD was not validated by quan-
titative PCR (see below).
We observed slightly different levels of miRNA 
expression between male and female BMC as illus-
trated by the heat map generated by GSEA (Fig. 1A), 
but the differences analyzed by SAM were not 
signiﬁ  cant (data not shown). Next, we stratiﬁ  ed 
NEC and AD miRNA signatures according to 
APOE4 status (Table 2). Similarly to the entire 
cohort, we found common miRNA upregulated in 
AD, with tendencies for over-representation of 
certain miRNA in the APOE4-negative (i.e. 
miR-34a, 517*, let-7f, 200a), and possibly the 
APOE4-positive (i.e. miR-371; miR-181b) strata.
We next performed a higher order analysis of the 
cohort’s miRNA expression signatures by hierarchical 
clustering using Pearson correlations (Fig. 1B). An 
apparent classiﬁ  cation of NEC and AD was obtained, 
although three female NEC signatures subgrouped 
with AD miRNA proﬁ  les. The complexity of the dif-
ferent levels of clusters may be related to the inherent 
experiment block effect existing between the 
MMchips. Sub-grouping for gender or using the sig-
niﬁ  cantly upregulated miRNAs of Table 1 did not 
improve the classiﬁ  cations (data not shown).
Real time PCR validation
The above comparison for the whole cohort was 
validated by real time PCR. Levels of selected 
miRNAs in 10 samples (NEC and AD) were deter-
mined by qRT-PCR, and the average Ct values were 
used to estimate the difference in expression levels 
between diagnostic groups (Fig. 2).
Of the ﬁ  ve selected miRNAs tested by qPCR, 
only one miRNA (miR-155) was not validated. 
Importantly, the delta Ct fold differences estimated 
in AD for miR-34a, 181b, 200a and let-7f corre-
sponded to their order of signiﬁ  cance reported in 
Table 1. The qPCR data suggest that the increase 
in miRNA levels in AD may be underestimated in 
the microarray platform (Table 1).
Target predictions
Target predictions for the signiﬁ  cantly upregulated 
miRNA in Alzheimer BMC ascertained from the 
miRBase (Sanger Institute, http://microrna.sanger.
ac.uk/targets/v4/) were compared with the down-
regulated mRNAs previously reported in Alzheimer 
BMC (Maes et al. 2006). Of the predicted hundreds 
of targets for any speciﬁ  c miRNA, a range of 10 
to 30 downregulated transcripts in Alzheimer 
Figure 1. Gene set enrichment analysis and hierarchical clustering 
of microRNA expression in Alzheimer BMC. (A) The signiﬁ  cantly 
upregulated miRNA in AD are ranked in order of signiﬁ  cance from 
top to bottom. (B) The hierarchical clustering of subjects was deter-
mined using Pearson correlation.
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BMC were correlated, however only transcripts 
with signiﬁ  cantly lower levels in AD are reported 
in Table 3. The percentage of targets per miRNA 
is reported in Table 1. Interestingly, miR-181b, 
which exhibited the greatest fold-increase expres-
sion in Alzheimer BMC, targeted the highest 
proportion of downregulated genes in AD BMC 
(31.1%), followed by miR-34a (21.7%). In con-
trast, targets of miR-200a correlated least with the 
genomic data (7.5%). Target genes with signiﬁ  -
cantly downregulated transcript levels in AD 
frequently correlated with miR-181b (NDUFS3, 
HSF2), let-7f (HERPUD1, TBPL1) and miR-34a 
(HNRPR, BTF3).
The functional categories for these putative 
targets are summarized in Figure 3. Interestingly, 
genes with multifunctional roles in Synapse Activ-
ity represented the most extensively targeted cat-
egory. The enriched GO categories speciﬁ  ed by 
GOTREE for the targeted downregulated genes 
were: Transcription (P = 0.001), Protein Transport 
(P = 0.006), and the Peroxisome (P = 0.005). The 
highest number of individual miRNAs targeting a 
common gene within the same functional category 
corresponded to Injury Response/Redox Homeo-
stasis. MicroRNAs let-7f, 34a 181b and 200a 
shared common targets in several functional 
categories (Table 3).
The enriched GO categories for the downregu-
lated targets identiﬁ  ed for some of the individual 
upregulated miRNAs were as follows: Cell 
Homeostasis and Peroxisome for miR-34a; 
Table 2. Altered miRNA expression in APOE4-negative and -positive strata
APOE4 status  MicroRNA  Fold change  Score (d)  q-value (%)
negative hsa-miR-34a  1.4  1.8  0.0
negative hsa-miR-517*  1.2  1.7  0.0
negative hsa-let-7f  1.2  1.5  0.0
negative hsa-miR-200a  1.2  1.4  0.0
     
positive hsa-miR-371  1.4  1.1 22.2
positive hsa-miR-181b  1.7  1.0 22.2
False discovery rates (q-values) were 0% in the negative stratum and 22.2% in the positive stratum of 4 and 4 signiﬁ  cant miRNAs 
respectively.
Figure 2. Quantitative real time PCR of miRNA levels in AD. Fold differences in miRNA levels between NEC and AD were estimated by the 
delta Ct method.
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Figure 3. Functional categories of predicted microRNA targets downregulated in Alzheimer BMC.  Targets of upregulated BMC miRNA were 
compared to previous downregulated mRNA data in Alzheimer BMC (Maes et al. 2006), and summarized according to percentage of targets 
per functional category. The average number of miRNAs targeting the same gene within each category is reported.
Cell Cycle and DNA Damage for miR-181b; and 
Vesicle Processes for miR-517*. Represented GO 
categories were also associated with miRNAs, such 
as: Cell Cycle with miR-200a and DNA Dam-
age with miR-517*.
Discussion
Our study was based on the same population 
described in a previous transcriptome analysis 
(Maes et al. 2006) in order to compare microRNA 
action and their target genes at the message level. 
We made a stringent sample selection based on: 
(1) well-ascertained cases and controls matched 
for ethnicity, gender and age and (2) excellent total 
RNA quality and yield of puriﬁ  ed microRNA for 
the screening of 462 currently-known human 
microRNA species. We found that human BMC 
expressed a broad range of miRNAs, representing 
20% of the 462 miRNA spotted on nitrocellulose 
membranes in the array format (Supplemental 
Table 2).
MicroRNA expression profiles have shown 
greater accuracy in classifying cancers than have 
gene expression proﬁ  les (Lu et al. 2005). Although 
our classiﬁ  cation of miRNA expression signatures 
may have been affected by experimental variations, 
we obtained relatively good discrimination of NEC 
vs. AD cases. However, the complexity and vari-
ability of miRNA expression observed between 
subjects could have also arisen from the diversity 
of cell types comprising the BMC fraction (Jison 
et al. 2004). It still remains to be determined 
whether the miRNA signature of a speciﬁ  c blood 
mononuclear cell type would be more effective in 
the classiﬁ  cation of neurodegenerative diseases.
Despite the heterogeneity of BMC, we observed 
a signiﬁ  cant increase in the expression of miR-34a 
and 181b in mild sporadic AD as compared to age-
matched normal controls. A higher upregulation of 
miR-181b in Alzheimer BMC may also occur in 
APOE4-positive AD subjects. However, the higher 
FDR of 22% and low number of APOE4-positive 
Functional categories targeted (%)
02468 1 0 1 2 1 4 1 6
CNS and synapse
Cell metabolism
Transcripion-translation
Unknown
Protein trafficking-processing 
Injury response-redox homeostasis
Inflammatory-immune response
Signal transduction
DNA repair
Cell proliferation
Mitochondria-bioenergetics
Lipid metabolism
Proteasome-lysosome
Cytoskeleton-cell adhesion
Cell survival program 1.0
1.0
1.0
1.3
1.3
1.0
1.0
1.0
1.2
1.6
1.1
1.5
1.2
1.3
1.3269
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Table 3. Predicted miRNA targets downregulated in Alzheimer BMC.
Upregulated   Target
a  Target Gene Name  Fold  Score  Function
microRNA     change  (d) 
Cell development and metabolism       
181b AHCY  S-adenosylhomocysteine    0.46  −1.14 methylation/
   hydrolase      homocysteine
34a  BCKDK  branched chain alpha-  0.56  −1.91  amino acid pathway
   ketoacid  dehydrogenase
   kinase
let-7f; 34a  FXYD2  FXYD domain containing  0.66  −1.61 ion  transport
    ion transport regulator 2
34a SHMT1  serine  hydroxymethyl-  0.75  −1.59 serine  catabolism
   transferase  1 
181b  GPI  glucose phosphate isomerase  0.75  −1.52 glycolysis
34a AMPD2  adenosine  monophosphate  0.50  −1.47 energy  metabolism
   deaminase  2      (brain)
181b; 517*  HMBS  hydroxymethylbilane synthase  0.35  −1.24 heme  biosynthesis
34a LTF  lactotransferrin  0.15  −0.93 iron  homeostasis 
34a CD151  CD151  antigen  0.59  −2.66  cell adhesion (sensory
         neuron)
181b NDUFS3  NADH  dehydrogenase  0.08  −1.19  mitochondrial complex I
    Fe-S protein 3
Cell survival program      
579 PSAP  prosaposin  0.79  −1.61 anti-apoptotic 
34a BIK  BCL2-interacting  killer  0.54  −1.01 apoptosis
CNS and synapse         
let-7f; 34a  CRB3  crumbs homolog 3  0.39  −2.19 tight  junction
34a  P2RY2  purinergic receptor P2Y,  0.51  −1.84 APP  processing
    G-protein coupled, 2
579  RXRG  retinoid X receptor, gamma  0.49  −1.74 synaptic  plasticity
34a GFAP  glial  ﬁ  brillary acidic protein  0.47  −1.65 myelination   
181b; 517*  ACTG1  actin, gamma 1  0.77  −1.63 axon  growth
34a HNRPR  heterogeneous  nuclear 0.45  −1.49  axon motor neuron
   ribonucleoprotein  R
DNA repair          
181b; 200a  MCM3  minichromosome maintenance  0.70  −1.68  DNA damage response
   deﬁ  cient 3 
181b  MMS19L  MMS19-like (MET18 homolog)  0.59  −1.39 DNA  repair 
Inﬂ  ammatory-immune response       
579 DDT  D-dopachrome  tautomerase  0.76  −2.68 inﬂ  ammation
let-7f; 34a  CHST12  carbohydrate sulfotransferase 12  0.79  −1.85 immune  response
517* LAMP2  lysosomal-associated  0.50  −1.73 immune  response
    membrane protein 2
181b SLA  Src-like-adaptor  0.53  −1.41 immune  response
Injury response-redox homeostasis     
let-7f; 200a  HERPUD1  homocysteine-inducible,  0.41  −2.26 stress  response
   ubiquitin-likedomainmember1 
517*  HMGN2  high-mobility group nucleosomal  0.71  −1.71 oxidative  stress
    binding domain 2
let-7f; 181b  TBPL1  TBP-like 1  0.41  −1.69 stress  response
181b  HSF2  heat shock transcription  0.34  −1.64 stress  response
   factor  2 
Lipid metabolism         
let-7f ELA3B  elastase  3B,  pancreatic  0.53  −2.87 cholesterol  biosynthesis
181b FDXR  ferredoxin  reductase  0.51  −1.85 cholesterol  biosynthesis
(Continued)270
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chips in the NEC group does not allow us to deter-
mine conclusively the impact of APOE4 status on 
miRNA expression. Nevertheless, the APOE4 
allele is associated with an earlier onset of the 
disease (Hsiung et al. 2004), and higher expression 
of miRNAs could occur in these subjects as sug-
gested by our results. If validated, induction of 
miRNA expression may provide a surrogate marker 
of AD progression.
In this regard, it is interesting to note that a 
reduction in dicer activity promotes tau toxicity in 
Drosophila (Bilen et al. 2006b). Thus, certain 
hallmark neuropathological features of AD may 
represent events of dysregulated miRNA process-
ing. A reduction of miRNA processivity should 
instead lead to a decrease in miRNA levels. In fact, 
increases in miRNAs levels were reported in 
human AD hippocampus (Lukiw, 2007), and this 
possible paradox in humans should be addressed 
in future investigations. However, the miRNAs 
observed in Alzheimer BMC differed from the few 
miRNAs screened in the latter study. In both stud-
ies, induction of speciﬁ  c miRNAs may contribute 
to the suppression of multiple mRNA species and 
thereby impact a host of cellular mechanisms 
(Lukiw, 2007). Moreover, concomitant induction 
of several miRNA species may act in an additive 
or synergistic manner to inhibit gene expression 
(Krek et al. 2005). In fact, studies have determined 
that individual microRNAs can downregulate 
Table 3. (Continued)
Upregulated   Target
a  Target Gene Name  Fold  Score  Function
microRNA     change  (d) 
let-7f; 34a  MECR  mitochondrial trans-2-  0.50  −1.17  fatty acid metabolism
   enoyl-CoA  reductase 
Proteasome-lysosome-transport      
579 UBE2M  ubiquitin-conjugating  enzyme  0.50  −2.13 ubiquitin  cycle
   E2M 
181b  DNAJC7  DnaJ (Hsp40) homolog,  0.76  −1.82 protein  folding
    subfamily C, member 7
181b  NDRG2  NDRG family member 2  0.43  −1.76 protein  chaperone
         (misfolded) 
579 SNX2  sorting  nexin  2  0.34  −1.68 protein  sorting
Signal transduction         
181b  AGGF1  Angiogenic factor with G  0.54  −1.44 signal  transduction
    patch and FHA domains 1
181b MAP3K6  mitogen-activated  protein  0.58  −0.93 signal  transduction
    kinase kinase kinase 6 
Transcripion-translation    
34a  BTF3  basic transcription factor 3  0.45  −3.31 transcription
200a DDX5  DEAD/H  (Asp-Glu-Ala-Asp/  0.73  −2.34 spliceosome
    His) box polypeptide 5
34a  IRF1  interferon regulatory factor 1  0.59  −1.46 transcription
let-7f; 181b  TAF1A  TATA box binding protein-  0.58  −1.35 transcription  (rRNA)
    assoc. factor, RNApol I, A
Unknown        
517*  MLF2  myeloid leukemia factor 2  0.71  −2.04 unknown
181b; 579  BEX2  Brain expressed X-linked 2  0.33  −1.89 unknown  (brain)
let7f; 181b; 579 SSX2  synovial sarcoma, X  0.46  −1.75 unknown
   breakpoint  2
517* ZNF691  zinc  ﬁ  nger protein 691  0.14  −1.60 unknown
181b  RBMXL1  RNA binding motif protein,  0.42  −1.27 unknown
   X-linked-like  1
let-7f, 517*  OBFC1  oligonucleotide/oligosaccharide-  0.55  −1.11 unknown
   bindingfoldcontaining1 
aUnderlined gene symbols indicate similar down-regulation in AD affected brains (Maes et al. 2006).271
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several mRNA species (Lim et al. 2005) and induce 
mRNA instability (Sood et al. 2006).
The 3' UTR of target genes and the cellular con-
text strongly inﬂ  uence the action of miRNA (Didi-
ano and Hobert, 2006), and our study provides 
insights leading to the identiﬁ  cation of probable 
miRNA targets in human BMC. We discerned a 
prevalence of putative downregulated genes in the 
functional categories of Synapse Activity, Transcrip-
tion, and Injury/Redox Homeostasis. Importantly, 
Cell Cycle and DNA Damage related GO categories 
are targeted by miR-181b, 200a, and 517*.
Taken together, these observations further sup-
port our model linking the development of AD 
pathology to systemic dysfunction in the cellular 
stress/antioxidant response and genomic mainte-
nance (Maes et al. 2006). These data are com-
mensurate with reports of augmented oxidative 
DNA and RNA damage and deﬁ  cient transcription 
and translation in AD brain and peripheral tissues 
(Markesbery and Lovell, 2006; Shan and Lin, 
2006). The latter impairments may, in turn, con-
tribute to the cytoskeletal abnormalities and 
neuroﬁ  brillary degeneration characteristic of AD-
affected neural tissues (Maes et al. 2006).
Caution must be exercised in extrapolating from 
BMC miRNA data sets to gene expression proﬁ  les 
in AD brain given the different 3' UTR regions 
inherent to neuronal mRNA relative to peripheral 
tissues (Sood et al. 2006). A wide array of miRNA 
species should be surveyed in AD-affected brain 
tissue to determine whether miRNA dysregulation 
exists therein comparable to that observed in the 
current Alzheimer BMC study.
The current study provides, to our knowledge, 
ﬁ  rst evidence of augmented microRNA expres-
sion in Alzheimer BMC, as well as the framework 
for future miRNA-target experiments on altered 
cellular functions related to this disease. For 
example, miRNAs may account for the suppres-
sion of mRNA species implicated in the cellular 
stress response and DNA repair previously 
reported in Alzheimer BMC (Maes et al. 2006). 
Dysregulation of BMC miRNA in sporadic AD 
may shed new light on the pathogenesis of AD 
and possibly provide useful diagnostic/prognostic 
biomarkers of this common afﬂ  iction.
Acknowledgments
The authors thank Drs Jin An, Suying Xu and Bo 
Yu for the production of the MMchip. The authors 
gratefully acknowledge the participation of the 
medical staff, neuropsychologists, nurses, patients, 
research coordinators and secretaries of the JGH/
McGill Memory Clinic. This work was supported 
by an internal grant from the Sir Mortimer B. 
Davis-Jewish General Hospital to HMS and 
Research-enhancement funding support from the 
School of Medicine of the University of Louisville 
to EW. None of the authors has any disclosures 
concerning any actual or potential conﬂ  icts of 
interest, and have conﬁ  rmed that no conﬂ  icts of 
interest exist.
References
Ambros, V. 2004. The functions of animal microRNAs. Nature, 431, 350–5.
Babak, T., Zhang, W., Morris, Q., Blencowe, B.J. and Hughes, T.R. 2004. 
Probing microRNAs with microarrays: tissue speciﬁ  city and func-
tional inference. Rna., 10, 1813–9.
Bilen, J., Liu, N. and Bonini, N.M. 2006a. A new role for microRNA path-
ways: modulation of degeneration induced by pathogenic human 
disease proteins. Cell Cycle, 5, 2835–8.
Bilen, J., Liu, N., Burnett, B.G., Pittman, R.N. and Bonini, N.M. 2006b. 
MicroRNA pathways modulate polyglutamine-induced neurodegen-
eration. Mol. Cell, 24, 157–63.
Boehm, M. and Slack, F. 2005. A developmental timing microRNA and its 
target regulate life span in C. elegans. Science, 310, 1954–7.
Chertkow, H., Bergman, H., Schipper, H.M., Gauthier, S., Bouchard, R., 
Fontaine, S. and Clarﬁ  eld, A.M. 2001. Assessment of suspected 
dementia. Canadian Journal of Neurological Sciences, 28 Suppl 1, 
S28–41.
Didiano, D. and Hobert, O. 2006. Perfect seed pairing is not a generally 
reliable predictor for miRNA-target interactions. Nat. Struct. Mol. 
Biol., 13, 849–51.
Folstein, M.F., Folstein, S.E. and Mchugh, P.R. 1975. “Mini-mental state”. 
A practical method for grading the cognitive state of patients for the 
clinician. J. Psychiatr. Res., 12, 189–98.
Hammond, S.M. 2006. RNAi, microRNAs, and human disease. Cancer 
Chemother Pharmacol., 58 Suppl 7, 63–8.
Hsiung, G.Y., Sadovnick, A.D. and Feldman, H. 2004. Apolipoprotein E 
epsilon4 genotype as a risk factor for cognitive decline and dementia: 
data from the Canadian Study of Health and Aging. Cmaj, 171, 
863–7.
Jison, M.L., Munson, P.J., Barb, J.J., Suffredini, A.F., Talwar, S., Logun, 
C., Raghavachari, N., Beigel, J.H., Shelhamer, J.H., Danner, R.L. 
and Gladwin, M.T. 2004. Blood mononuclear cell gene expression 
proﬁ  les characterize the oxidant, hemolytic, and inﬂ  ammatory stress 
of sickle cell disease. Blood, 104, 270–80.
Kamboh, M.I. 2004. Molecular genetics of late-onset Alzheimer’s disease. 
Ann. Hum. Genet., 68, 381–404.
Keller, J.N. 2006. Interplay Between Oxidative Damage, Protein Synthesis, 
and Protein Degradation in Alzheimer’s Disease. Journal of Bio-
medicine and Biotechnology, Volume 2006, 1–3.
Krek, A., Grun, D., Poy, M.N., Wolf, R., Rosenberg, L., Epstein, E.J., 
Macmenamin, P., Da Piedade, I., Gunsalus, K.C., Stoffel, M. and 
Rajewsky, N. 2005. Combinatorial microRNA target predictions. Nat. 
Genet., 37, 495–500.
Lacelle, C., Riol, H., Xu, S., Tang, Y.J., Wang, Y.S., Chuang, Y.L., Lin, H.S., 
Chang, M.C., Liang, J. and Wang, E. 2002. Blood-sample processing 
for the study of age-dependent gene expression in peripheral blood 
mononuclear cells. J. Gerontol. A. Biol. Sci. Med. Sci., 57, B285–7.
Lee, R.C., Feinbaum, R.L. and Ambros, V. 1993. The C. elegans heteroch-
ronic gene lin-4 encodes small RNAs with antisense complementar-
ity to lin-14. Cell, 75, 843–54.272
Schipper et al
Gene Regulation and Systems Biology 2007:1 
Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, 
J., Bartel, D.P., Linsley, P.S. and Johnson, J.M. 2005. Microarray 
analysis shows that some microRNAs downregulate large numbers 
of target mRNAs. Nature, 433, 769–73.
Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., 
Sweet-Cordero, A., Ebert, B.L., Mak, R.H., Ferrando, A.A., Downing, 
J.R., Jacks, T., Horvitz, H.R. and Golub, T.R. 2005. MicroRNA 
expression proﬁ  les classify human cancers. Nature, 435, 834–8.
Lukiw, W.J. 2007. Micro-RNA speciation in fetal, adult and Alzheimer’s 
disease hippocampus. Neuroreport, 18, 297–300.
Maes, O.C., Xu, S., Yu, B., Chertkow, H.M., Wang, E. and Schipper, H.M. 
2006. Transcriptional proﬁ  ling of Alzheimer blood mononuclear cells 
by microarray. Neurobiol Aging.
Markesbery, W.R. and Lovell, M.A. 2006. DNA oxidation in Alzheimer’s 
disease. Antioxid Redox Signal, 8, 2039–45.
Mckhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and 
Stadlan, E.M. 1984. Clinical diagnosis of Alzheimer’s disease: report 
of the NINCDS-ADRDA Work Group under the auspices of Depart-
ment of Health and Human Services Task Force on Alzheimer’s 
Disease. Neurology, 34, 939–44.
Ouellet, D.L., Perron, M.P., Gobeil, L.A., Plante, P. and Provost, P. 2006. 
MicroRNAs in Gene Regulation: When the Smallest Governs It All. 
J. Biomed. Biotechnol., 2006, 69616.
Park, W., Li, J., Song, R., Messing, J. and Chen, X. 2002. CARPEL FAC-
TORY, a Dicer homolog, and HEN1, a novel protein, act in microRNA 
metabolism in Arabidopsis thaliana. Curr. Biol., 12, 1484–95.
Pasinetti, G.M. 2001. Use of cDNA Microarray in the Search for Molecular 
Markers Involved in the Onset of Alzheimer’s Disease Dementia. 
Journal of Neuroscience Research, 65, 471–476.
Puchades, M., Hansson, S.F., Nilsson, C.L., Andreasen, N., Blennow, K. 
and Davidsson, P. 2003. Proteomic studies of potential cerebrospinal 
ﬂ  uid protein markers for Alzheimer’s disease. Brain Res. Mol. Brain 
Res., 118, 140–6.
Ruvkun, G., Wightman, B. and Ha, I. 2004. The 20 years it took to recognize 
the importance of tiny RNAs. Cell, 116, S93-6, 2 p following S96.
Scherzer, C.R., Offe, K., Gearing, M., Rees, H.D., Fang, G., Heilman, C.J., 
Schaller, C., Bujo, H., Levey, A.I. and Lah, J.J. 2004. Loss of apoli-
poprotein E receptor LR11 in Alzheimer disease. Arch. Neurol., 61, 
1200–5.
Selkoe, D.J. 1991. The molecular pathology of Alzheimer’s disease. Neuron., 
6, 487–98.
Shan, X. and Lin, C.L. 2006. Quantiﬁ  cation of oxidized RNAs in Alzheim-
er’s disease. Neurobiol Aging, 27, 657–62.
Sood, P., Krek, A., Zavolan, M., Macino, G. and Rajewsky, N. 2006. Cell-
type-speciﬁ  c signatures of microRNAs on target mRNA expression. 
Proc. Natl. Acad. Sci. U.S.A., 103, 2746–51.
Strauss, W.M., Chen, C., Lee, C.T. and Ridzon, D. 2006. Nonrestrictive 
developmental regulation of microRNA gene expression. Mamm. 
Genome., 17, 833–40.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., 
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, 
E.S. and Mesirov, J.P. 2005. Gene set enrichment analysis: A knowl-
edge-based approach for interpreting genome-wide expression pro-
ﬁ  les. Proc. Natl. Acad. Sci. U.S.A., 102 15545–15550.
Wang, E., Lacelle, C., Xu, S., Zhao, X. and Hou, M. 2002. Designer micro-
arrays: from soup to nuts. J. Gerontol. A. Biol. Sci. Med. Sci., 57, 
B400–5.273
MicroRNA proﬁ  ling in Alzheimer BMC
Gene Regulation and Systems Biology 2007:1 
Supplemental Materials
Supplemental Table 1. Demographics of cohort and small RNA yields.
Diagnosis  Subject  Gender  Age  Education  MMSE  APOE  Total RNA  Small RNA  Ratio
a
 ID           (µg)  (µg)  (%)
NEC 967  F  80  11  29  2,3  41.7 1.2  2.9
NEC 944  F  68  18  30  3,3  80.4 1.7  2.1
NEC 1014  F  83  21  29  3,3  73.6 2.1  2.8
NEC 3R447  F  78  17  29  3,3  23.5 1.1  4.5
NEC 3R464    F  78  10  28  3,3  115.8  1.2  1.0
NEC R787  F  87  15  30  3,3  26.8 1.7  6.5
NEC 1005  F  68  15  30  3,4  97.0 1.2  1.3
NEC 1025  F  71  15  28  3,4  51.1 3.4  6.6
              
NEC 917  M 72  15  29  3,3  23.5 1.8  7.7
NEC 923  M 84  12  27  3,3  43.2 1.0  2.2
NEC 942  M 72  11  29  3,3  57.8 1.9  3.3
NEC 948  M 80  16  30  3,3  34.9 1.4  4.1
NEC R887  M 74  20  30  3,3  56.4 3.1  5.5
NEC 951  M 80  16  30  3,4  15.1 1.1  7.0
NEC R265  M 73  22  30  3,4  44.3 1.0  2.3
NEC 3R446  M 71  9  29  4,4  62.9 1.7  2.6
              
AD 940  F  75  13  21  3,4  52.9  1.1  2.1
AD 961  F  79  10  23  3,4  100.1  1.8  1.8
AD 939  F  78  6  27  3,3  76.9  1.1  1.4
AD 2R411  F  80  14  24  3,3  38.4  2.6  6.8
AD 1049  F  84  16  24  2,4  18.9  2.6  13.9
AD 1057  F  72  11  27  3,4  37.6  1.1  2.8
AD 928  F  81  13  13  2,2  39.4  1.1  2.9
AD 1033  F  88  12  nd  3,3  48.0  0.9  1.9
              
AD 906  M  73  14  25  3,3  28.1  1.3  4.7
AD 925  M  80  15  28  3,3  52.1  1.4  2.6
AD 943  M  75  20  17  3,3  77.8  1.6  2.0
AD 989  M  69  11  21  4,4  36.7  0.9  2.6
AD 1018  M  76  12  23  4,4  34.3  2.8  8.1
AD 1022  M  84  12  22  3,4  61.0  2.5  4.1
AD 2R377  M  81  15  26  3,4  117.0  1.3  1.1
AD 3R386  M  79  7  25  3,3  73.8  1.8  2.5
aPercentage of small RNA over total RNA.274
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Supplemental Table 2. miRNA expression in elderly human blood mononuclear cells.
High (intensity 20–8)
a.  Medium (intensity <7)  Low (intensity <3)
hsa-let-7c hsa-let-7g  hsa-let-7i
hsa-let-7f hsa-miR-34a  hsa-miR-10a
hsa-miR-10b hsa-miR-34b  hsa-miR-18b
hsa-miR-18a hsa-miR-92b  hsa-miR-23b
hsa-miR-27b hsa-miR-125b  hsa-miR-26a
hsa-miR-95 hsa-miR-136  hsa-miR-93
hsa-miR-137 hsa-miR-181b  hsa-miR-107
hsa-miR-188 hsa-miR-182  hsa-miR-146a
hsa-miR-200b hsa-miR-195  hsa-miR-148a
hsa-miR-373* hsa-miR-200a  hsa-miR-152
hsa-miR-376a* hsa-miR-219  hsa-miR-155
hsa-miR-377 hsa-miR-373  hsa-miR-192
hsa-miR-380-5p hsa-miR-489  hsa-miR-363
hsa-miR-509 hsa-miR-515-5p  hsa-miR-371
hsa-miR-510 hsa-miR-518a  hsa-miR-424
hsa-miR-517* hsa-miR-520b  hsa-miR-431
hsa-miR-520h hsa-miR-539  hsa-miR-449b
hsa-miR-523 hsa-miR-548b  hsa-miR-493-3p
hsa-miR-551a hsa-miR-562  hsa-miR-513
hsa-miR-561 hsa-miR-577  hsa-miR-569
hsa-miR-574 hsa-miR-579  hsa-miR-575
hsa-miR-582 hsa-miR-600  hsa-miR-581
hsa-miR-585 hsa-miR-607  hsa-miR-587
hsa-miR-591 hsa-miR-620  hsa-miR-605
hsa-miR-598 hsa-miR-623  hsa-miR-608
hsa-miR-603 hsa-miR-624  hsa-miR-638
hsa-miR-609 hsa-miR-627  hsa-miR-652
hsa-miR-612 hsa-miR-646 
hsa-miR-621 hsa-miR-647 
hsa-miR-633 hsa-miR-653 
hsa-miR-641 hsa-miR-661 
hsa-miR-649  
hsa-miR-659  
hsa-miR-660  
aHybridization intensity after DIG immunodetection (see Methods section).